Recent Developments in Rare Ovarian Carcinosarcoma: Literature Review and Case Report

Area of Science:

• Gynecologic Oncology
• Rare Cancers
• Surgical Pathology

Background:

• Ovarian carcinosarcoma (OCS) is a rare, aggressive gynecologic malignancy with both epithelial and mesenchymal components.
• Typically presents at advanced stages with poor patient outcomes.
• This study reviews a case and current literature on OCS from 2000-2024.

Purpose of the Study:

• To present a case of ovarian carcinosarcoma (OCS) initially presenting with deep vein thrombosis.
• To contextualize the case with a literature review on OCS pathogenesis, treatment, and outcomes.
• To explore potential therapeutic targets and improve long-term survival strategies.

Main Methods:

• Comprehensive case report detailing diagnostic imaging, surgical pathology, and treatment course.
• Focused literature review of ovarian carcinosarcoma from 2000 to 2024.
• Analysis of OCS pathogenesis, current treatment protocols, and prognostic factors.

Main Results:

• The patient's tumor was predominantly sarcomatous with high-grade serous features, responding to platinum/taxane chemotherapy.
• Majority of OCS cases (over 60%) present at advanced stages; suboptimal cytoreduction correlates with worse prognosis.
• Up to 64% of OCS tumors may exhibit homologous recombination deficiency, suggesting potential for PARP inhibitor therapy, though 5-year survival remains below 45%.

Conclusions:

• Optimal debulking surgery and platinum-based chemotherapy are the cornerstones of OCS treatment.
• Homologous recombination deficiency and BRCA mutations are emerging molecular targets for novel therapies.
• Multidisciplinary care and prospective studies are crucial for improving outcomes in ovarian carcinosarcoma.